Cancer Diagnostics Market

Cancer Diagnostics Market by Product (Consumables (Anitibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals)- Global Forecasts to 2026

Report Code: MD 3480 Apr, 2021, by marketsandmarkets.com

[280 Pages Report] The global cancer diagnostics market size is projected to reach USD 26.6 billion by 2026 from USD 17.2 billion in 2021, at a CAGR of 11.5% during the forecast period. Growth of the market is driven mainly by increasing incidence of cancer and growth in the number of private diagnostic laboratories.

Cancer Diagnostics Market

To know about the assumptions considered for the study, download the pdf brochure

Covid -19 Impact on the Cancer Diagnostics Market

With the WHO officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies and small startups has stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus. The COVID-19 outbreak has significantly impacted the availability of hospital resources worldwide. This has been primarily managed by dramatically reducing inpatient and outpatient services for other diseases and implementing infection prevention and control measures. The number of cancer screening and diagnostic procedures declined precipitously, with countries worldwide being affected by the pandemic

Global Cancer Diagnostics Market Dynamics

DRIVER: Growth in the number of private diagnostic centers

The number of private diagnostic centers is increasing across the globe as there is a rising demand for diagnostic imaging procedures and a growing burden on public hospitals due to the limited number of imaging modalities at their disposal. In January 2021, FUJIFILM Corporation opened NURA, a medical screening center focusing on cancer screening in Bangalore, India. This medical screening center is operated by FUJIFILM DKH LLP (FUJIFILM DKH) and Dr. Kutty’s Healthcare (DKH). FUJIFILM DKH LLP (FUJIFILM DKH) is a joint venture of FUJIFILM and Dr. Kutty’s Healthcare (DKH), which runs hospitals and screening centers in India and the Middle East.

OPPORTUNITY: Recommendations for cancer screening

In an attempt to detect cancer in the early stages and bring down the mortality rate, governments in developed countries and primary care doctors are recommending cancer screening tests for patients. The US Preventive Services Task Force (USPSTF) recommends screening for colorectal cancer starting at 50 years of age to 75 years of age in the US as a means of preventing disease incidence and ensuring early-stage treatment. Canada has also implemented guidelines for biennial colorectal cancer screening for people aged 50 to 74 years.

CHALLENGE: Increasing adoption of refurbished diagnostic imaging systems

Many hospitals in developing countries cannot invest in diagnostic imaging equipment due to their higher cost, poor reimbursement rates, and budgetary constraints. However, due to the high demand for diagnostic imaging procedures in these nations, hospitals that cannot afford to invest in new imaging systems prefer to opt for refurbished ones. Refurbished systems are priced lower than new systems and are approximately in the range of 40% to 60% of the original price of the equipment.

Owing to this, many market leaders are now promoting refurbished devices through various programs. For instance, Siemens’ Medical Proven Excellence Program, GE Healthcare’s Gold Seal Program, and Philips’ Diamond Select Program are some noteworthy global refurbishing programs that promote the utilization of refurbished diagnostic imaging systems.

The consumables segment is expected to grow at the highest CAGR during the forecast period

Based on the product, the cancer diagnostics market is segmented into consumables and instruments. The consumables segment is projected to witness the highest growth during the forecast period. The repeated purchase and high consumption, and the high prevalence of diseases the major factors supporting the growth of this segment.

The technology segment accounted for the largest share of the cancer diagnostics market in 2020

By technology, the cancer diagnostics market is segmented IVD testing, imaging based and biopsy technique. The IVD testing segment accounted for the largest market share in 2020. The large share of this segment can be attributed to increasing incidence of cancer.

Hospitals for the largest share of the cancer diagnostics market in 2020

Based on end-users, the cancer diagnostics market is segmented into hospitals and diagnostic laboratories. The hospitals segment accounted for the largest share of the cancer diagnostics market in 2020. The increasing number of patients visiting hospitals, rising number of in-house diagnostic procedures performed in hospitals, and growing awareness regarding early diagnosis is are the major driving factor for this market.

Cancer Diagnostics Market by Region

North America accounted for the largest share of the cancer diagnostics market in 2020

Based on the region, the cancer diagnostics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2020, North America accounted for the largest share of the cancer diagnostics market. The large share of North America can be attributed to factors such as increasing incidence of cancer and technological advancement.

Key Market Players

Some of the major players operating in this market are GE Healthcare (US), Roche Diagnostics (Switzerland), and  Becton, Dickinson and Company (US). In 2020, GE Healthcare held the leading position in the  market. The company has a strong geographic presence across the US, Asia, Europe, Middle East and Africa, & the Americas. Moreover, the company’s strong brand recognition and comprehensive product portfolio in the cancer diagnostics market is its key strength. BD held the second position in the cancer diagnostics market in 2020.

Scope of the report

Report Metric

Details

Market Size Available for Years

2019–2026

Base Year Considered

2020

Forecast Period

2021–2026

Forecast Units

Value (USD)

Segments Covered

Products, Cell Type, Application, End User and Region

Geographies Covered

North America (US, Canada), Europe (Germany, France, UK, Spain, Italy, and RoE), APAC (China, India, Japan and the RoAPAC), and Rest of the World

Companies Covered

GE Healthcare (US), Abbott Laboratories (US), Hologic Inc. (US), Agilent Technologies Inc.(US), Roche Diagnostics (Switzerland), FUJIFILM Corporation (Japan), Danaher Corporation (US), DiaSorin S.P.A. (Italy), Myriad Genetics Inc. (US), Siemens Healthineers AG (Germany), BD (US), bioMιrieux SA (France), Bio-Rad Laboratories (US), Cancer Diagnostics Inc. (US), Vela Diagnostics (Singapore), Roche Diagnostics (Switzerland), AMOY Diagnostics CO. LTD. (China), Quidel Corporation (US), Bio SB (US), Biocartis NV (Belgium), Exact Science (US)

 

This research report categorizes the cancer diagnostics market into the following segments and subsegments:

Product

  • Consumables
    • Antibodies
    • Kits & Reagents
    • Probes
    • Other Consumables
  • Instruments
    • Pathology-based Instruments
      • Slide Staining Systems
      • Tissue Processing Systems
      • Cell Processors
      • PCR Instruments
      • NGS Instruments
      • Microarrays
      • Other Pathology-based Instruments
    • Imaging Instruments
      • CT Systems
      • Ultrasound Systems
      • MRI Systems
      • Mammography Systems
      • Nuclear Imaging Systems
  • Biopsy Instruments

Technology

  • IVD Testing
    • Polymerase Chain Reaction (PCR)
    • In Situ Hybridization (ISH)
    • Immunohistochemistry (IHC)
    • Next-generation Sequencing (NGS)
    • Microarrays
    • Flow Cytometry
    • Immunoassays
    • Other IVD Testing Technologies
  • Imaging
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    •  Positron Emission Tomography (PET)
    • Mammography
    • Ultrasound
  • Biopsy Technique
Application
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Other Cancers
End User
  • Hospitals
  • Diagnostic Laboratories

Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • RoE
  • Asia Pacific
    • China
    • India
    • Japan
    • RoAPAC
  • Rest of the World
    • Latin America
    • Middle East and Africa

Recent Developments:

  • In 2020, GE Healthcate entered into partnership with GenesisCare to improve patient outcomes for the two biggest health burdens globally, cancer and heart disease. GE Healthcare will provide CT, MRI, PET/CT, SPECT, digital mammography, and ultrasound equipment to GenesisCare’s 440+ cancer and cardiovascular disease treatment centers across Australia, the US, the UK, and Spain
  • In 2020, Roche Diagnostics entered into partnership with Illumina to provide broad access to clinical oncology next-generation sequencing

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 27)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           1.3.1 MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 MARKET STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 31)
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
    2.2 MARKET SIZE ESTIMATION
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 COVID-19 HEALTH ASSESSMENT
    2.7 COVID-19 ECONOMIC ASSESSMENT
    2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO

3 EXECUTIVE SUMMARY (Page No. - 44)

4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 CANCER DIAGNOSTICS MARKET OVERVIEW
    4.2 CANCER DIAGNOSTICS MARKET, BY PRODUCT
    4.3 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY, 2020
    4.4 GEOGRAPHICAL SNAPSHOT OF THE CANCER DIAGNOSTICS MARKET

5 MARKET OVERVIEW (Page No. - 51)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidence of cancer
                    5.2.1.2 Growth in the number of private diagnostic centers
                    5.2.1.3 Availability of reimbursement
           5.2.2 RESTRAINTS
                    5.2.2.1 High capital investments and low cost-benefit ratio for biomarkers
                    5.2.2.2 High cost of diagnostic imaging systems
                    5.2.2.3 Product recalls and failure
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing focus on personalized medicine
                    5.2.3.2 Companion diagnostics
                    5.2.3.3 Recommendations for cancer screening
                    5.2.3.4 Emerging countries
           5.2.4 CHALLENGES
                    5.2.4.1 Increasing adoption of refurbished diagnostic imaging systems
                    5.2.4.2 Lack of skilled professionals
                    5.2.4.3 Inadequate infrastructure and low awareness in middle- and low-income countries
           5.2.5 TRENDS
                    5.2.5.1 Rental agreements
    5.3 COVID-19 IMPACT ANALYSIS
    5.4 VALUE CHAIN ANALYSIS
    5.5 SUPPLY CHAIN ANALYSIS
    5.6 PORTER’S FIVE FORCES ANALYSIS
           5.6.1 THREAT FROM NEW ENTRANTS
           5.6.2 INTENSITY OF COMPETITIVE RIVALRY
           5.6.3 BARGAINING POWER OF BUYERS
           5.6.4 BARGAINING POWER OF SUPPLIERS
           5.6.5 THREAT FROM SUBSTITUTES
    5.7 TECHNOLOGY ANALYSIS
    5.8 REGULATORY LANDSCAPE
    5.9 PATENT ANALYSIS
    5.10 TRADE ANALYSIS
           5.10.1 TRADE ANALYSIS FOR MAMMOGRAPHY SYSTEMS
           5.10.2 TRADE ANALYSIS FOR MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS
    5.11 PRICING ANALYSIS
    5.12 ECOSYSTEM ANALYSIS: CANCER DIAGNOSTICS MARKET
           5.12.1 ROLE IN ECOSYSTEM
    5.13 YCC SHIFT

6 CANCER DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 69)
    6.1 INTRODUCTION
    6.2 CONSUMABLES
           6.2.1 ANTIBODIES
                    6.2.1.1 Antibodies accounted for the largest share of the cancer diagnostic consumables market in 2020
           6.2.2 KITS & REAGENTS
                    6.2.2.1 Use of kits is increasing among end users owing to their ease of use
           6.2.3 PROBES
                    6.2.3.1 Abbott and Agilent Technologies are some of the leading players operating in this market segment
           6.2.4 OTHER CONSUMABLES
    6.3 INSTRUMENTS
           6.3.1 PATHOLOGY-BASED INSTRUMENTS
                    6.3.1.1 Slide staining systems
                               6.3.1.1.1 Slide staining systems accounted for the largest share of the pathology-based instruments market
                    6.3.1.2 Tissue processing systems
                               6.3.1.2.1 Tissue processing systems are used for the automatic processing of tissue samples
                    6.3.1.3 Cell processors
                               6.3.1.3.1 Cell processors are used to remove unwanted matter from cytology samples
                    6.3.1.4 PCR instruments
                               6.3.1.4.1 Cost-effectiveness of PCR is driving the growth of this market segment
                    6.3.1.5 NGS instruments
                               6.3.1.5.1 NGS is an emerging technology for cancer diagnostics
                    6.3.1.6 Microarrays
                               6.3.1.6.1 DNA microarrays are useful for the determination of primary sites in metastatic carcinomas
                    6.3.1.7 Other pathology-based instruments
           6.3.2 IMAGING INSTRUMENTS
                    6.3.2.1 CT systems
                               6.3.2.1.1 Technological advancements in CT to drive the growth of this market segment
                    6.3.2.2 Ultrasound systems
                               6.3.2.2.1 Increasing incidence of cancer to drive the growth of this market segment
                    6.3.2.3 MRI systems
                               6.3.2.3.1 Use of MRI in cancer diagnostics has increased over the years
                    6.3.2.4 Mammography systems
                               6.3.2.4.1 Increasing incidence of breast cancer to drive the growth of this market segment
                    6.3.2.5 Nuclear imaging systems
                               6.3.2.5.1 Technological advancements in nuclear imaging systems to drive the growth of this market segment
           6.3.3 BIOPSY INSTRUMENTS
                    6.3.3.1 Increasing prevalence of cancer to drive the growth of this market segment

7 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 85)
    7.1 INTRODUCTION
    7.2 IVD TESTING
           7.2.1 POLYMERASE CHAIN REACTION
                    7.2.1.1 Physicians prefer PCR-based diagnostic tests as they provide simple representations of genomic data
           7.2.2 IN SITU HYBRIDIZATION
                    7.2.2.1 ISH is used for the identification of specific mRNA species within sample cells
           7.2.3 IMMUNOHISTOCHEMISTRY
                    7.2.3.1 Increasing use of IHC tests for cancer diagnostics to boost the market growth
           7.2.4 NEXT-GENERATION SEQUENCING
                    7.2.4.1 NGS dominated the IVD testing market in 2020
           7.2.5 IMMUNOASSAY
                    7.2.5.1 Immunoassay segment accounted for the second-largest share of the cancer diagnostics market for IVD testing
           7.2.6 MICROARRAY
                    7.2.6.1 Cost-effectiveness of the microarray technology to support market growth
           7.2.7 FLOW CYTOMETRY
                    7.2.7.1 Flow cytometry tools help to detect the number of chromosomes to determine the malignancy of a tumor
           7.2.8 OTHER IVD TECHNOLOGIES
    7.3 IMAGING TECHNOLOGIES
           7.3.1 MAGNETIC RESONANCE IMAGING
                    7.3.1.1 Technological advancements to boost the growth of the MRI market
           7.3.2 COMPUTED TOMOGRAPHY
                    7.3.2.1 CT is a widely used technique in cancer diagnostics
           7.3.3 NUCLEAR IMAGING
                    7.3.3.1 PET is a widely used nuclear imaging technique in cancer diagnostics
           7.3.4 MAMMOGRAPHY
                    7.3.4.1 Increasing government initiativeS for breast cancer screening to drive the growth of this market segment
           7.3.5 ULTRASOUND
                    7.3.5.1 Adoption of POC ultrasound for diagnostic purposeS to suppoRt market growth
    7.4 BIOPSIES

8 CANCER DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 102)
    8.1 INTRODUCTION
    8.2 BREAST CANCER
           8.2.1 BREAST CANCER SEGMENT TO ACCOUNT FOR THE LARGEST SHARE DURING THE FORECAST PERIOD
    8.3 LUNG CANCER
           8.3.1 LUNG CANCER SEGMENT ACCOUNTED FOR THE SECOND-LARGEST SHARE IN 2020
    8.4 COLORECTAL CANCER
           8.4.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO DRIVE MARKET GROWTH
    8.5 MELANOMA
           8.5.1 INCREASING INCIDENCE OF MELANOMA TO DRIVE MARKET GROWTH
    8.6 OTHER CANCERS

9 CANCER DIAGNOSTICS MARKET, BY END USER (Page No. - 109)
    9.1 INTRODUCTION
    9.2 HOSPITALS
           9.2.1 HOSPITALS ARE THE LARGEST END USERS OF CANCER DIAGNOSTIC PRODUCTS
    9.3 DIAGNOSTIC LABORATORIES
           9.3.1 INCREASING INCIDENCE OF CANCER TO DRIVE THE GROWTH OF THIS SEGMENT

10 CANCER DIAGNOSTICS MARKET, BY REGION (Page No. - 112)
     10.1 INTRODUCTION
     10.2 NORTH AMERICA
             10.2.1 CANCER DIAGNOSTICS MARKET, BY REGION
                        10.2.1.1 US is expected to be dominant the North American market
             10.2.2 NORTH AMERICA
                        10.2.2.1 High prevalence of cancer in Canada is expected to support market growth
     10.3 EUROPE
             10.3.1 CANADA
                        10.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth
             10.3.2 EUROPE
                        10.3.2.1 Government initiatives to drive market growth in the UK
             10.3.3 Availability of reimbursements for colorectal cancer screening to drive market growth
                        10.3.3.1 Increasing government funding for cancer diagnosis and prevention to support the market growth
             10.3.4 Government initiatives to drive market growth in the UK
                        10.3.4.1 High incidence of cancer to support the market growth in Italy
             10.3.5 Increasing government funding for cancer diagnosis and prevention to support the market growth
                        10.3.5.1 High incidence of chronic diseases to drive the market growth in Spain
             10.3.6 High incidence of cancer to support the market growth in Italy
     10.4 ASIA PACIFIC
             10.4.1 High incidence of chronic diseases to drive the market growth in Spain
                        10.4.1.1 Increasing healthcare expenditure to drive market growth in China
             10.4.2 ASIA PACIFIC
                        10.4.2.1 Advanced healthcare infrastructure to support market growth in Japan
             10.4.3 Increasing healthcare expenditure to drive market growth in China
                        10.4.3.1 Expanding healthcare sector in the country to drive market growth
             10.4.4 Advanced healthcare infrastructure to support market growth in Japan
     10.5 REST OF THE WORLD
             10.5.1 Expanding healthcare sector in the country to drive market growth
                        10.5.1.1 Increasing number of cancer screening programs to support market growth
             10.5.2 REST OF THE WORLD
                        10.5.2.1 Increasing incidence of cancer in the Middle East & Africa to drive market growth

11 COMPETITIVE LANDSCAPE (Page No. - 194)
     11.1 OVERVIEW
     11.2 MARKET SHARE ANALYSIS
     11.3 COMPANY EVALUATION MATRIX
             11.3.1 OVERVIEW
             11.3.2 MARKET SHARE ANALYSIS
             11.3.3 COMPANY EVALUATION MATRIX
             11.3.4 STARS
     11.4 COMPETITIVE LEADERSHIP MAPPING (SMES/ START-UPS)
             11.4.1 PERVASIVE PLAYERS
             11.4.2 PARTICIPANTS
             11.4.3 COMPETITIVE LEADERSHIP MAPPING (SMES/ START-UPS)
             11.4.4 PROGRESSIVE COMPANIES
     11.5 COMPETITIVE SCENARIO
             11.5.1 RESPONSIVE COMPANIES
             11.5.2 DYNAMIC COMPANIES
             11.5.3 COMPETITIVE SCENARIO
             11.5.4 PRODUCT LAUNCHES & APPROVALS

12 COMPANY PROFILES (Page No. - 208)
     12.1 KEY PLAYERS
             12.1.1 COMPANY FOOTPRINT
                        12.1.1.1 Business overview
                        12.1.1.2 Products offered
                        12.1.1.3 Recent developments
                        12.1.1.4 SWOT analysis
                        12.1.1.5 Right to win
             12.1.2 Recent developments
                        12.1.2.1 Business overview
                        12.1.2.2 Products offered
                        12.1.2.3 SWOT analysis
                        12.1.2.4 Right to win
             12.1.3 Products offered
                        12.1.3.1 Business overview
                        12.1.3.2 Products offered
                        12.1.3.3 Recent developments
                        12.1.3.4 SWOT analysis
                        12.1.3.5 Right to win
             12.1.4 Recent developments
                        12.1.4.1 Business overview
                        12.1.4.2 Products offered
                        12.1.4.3 Recent developments
                        12.1.4.4 SWOT analysis
                        12.1.4.5 Right to win
             12.1.5 Recent developments
                        12.1.5.1 Business overview
                        12.1.5.2 Products offered
                        12.1.5.3 Recent developments
                        12.1.5.4 SWOT analysis
                        12.1.5.5 Right to win
             12.1.6 Recent developments
                        12.1.6.1 Business overview
                        12.1.6.2 Products offered
             12.1.7 ABBOTT LABORATORIES
                        12.1.7.1 Business overview
                        12.1.7.2 Products offered
                        12.1.7.3 Recent developments
             12.1.8 Business overview
                        12.1.8.1 Business overview
                        12.1.8.2 Products offered
                        12.1.8.3 Recent developments
             12.1.9 Business overview
                        12.1.9.1 Business overview
                        12.1.9.2 Products offered
                        12.1.9.3 Recent developments
             12.1.10 Business overview
                        12.1.10.1 Business overview
                        12.1.10.2 Products offered
                        12.1.10.3 Recent developments
             12.1.11 Business overview
                        12.1.11.1 Business overview
                        12.1.11.2 Products offered
             12.1.12 DIASORIN S.P.A.
                        12.1.12.1 Business overview
                        12.1.12.2 Products offered
                        12.1.12.3 Recent developments
             12.1.13 Business overview
                        12.1.13.1 Business overview
                        12.1.13.2 Products offered
                        12.1.13.3 Recent developments
             12.1.14 Business overview
                        12.1.14.1 Business overview
                        12.1.14.2 Products offered
             12.1.15 BIOMΙRIEUX SA
                        12.1.15.1 Business overview
                        12.1.15.2 Products offered
                        12.1.15.3 Recent developments
     12.2 START-UP/SME PLAYERS
             12.2.1 Products offered
                        12.2.1.1 Business overview
                        12.2.1.2 Products offered
             12.2.2 QUIDEL CORPORATION
                        12.2.2.1 Business overview
                        12.2.2.2 Products offered
                        12.2.2.3 Recent developments
             12.2.3 Business overview
                        12.2.3.1 Business overview
                        12.2.3.2 Products offered
                        12.2.3.3 Recent developments
             12.2.4 Business overview
                        12.2.4.1 Business overview
                        12.2.4.2 Products offered
             12.2.5 CANCER DIAGNOSTICS INC.
                        12.2.5.1 Business overview
                        12.2.5.2 Products offered
                        12.2.5.3 Recent developments
             12.2.6 Business overview
                        12.2.6.1 Business overview
                        12.2.6.2 Products offered
             12.2.7 BIO-RAD LABORATORIES
                        12.2.7.1 Business overview
                        12.2.7.2 Products offered
             12.2.8 BIO SB
                        12.2.8.1 Business overview
                        12.2.8.2 Products offered
                        12.2.8.3 Recent developments

13 APPENDIX (Page No. - 271)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS


LIST OF TABLES (300 Tables)

TABLE 1 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
TABLE 3 NUMBER OF PATHOLOGISTS PER 10,000 POPULATION, BY COUNTRY, 2018
TABLE 4 IMPORT DATA FOR MAMMOGRAPHY SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
TABLE 5 EXPORT DATA FOR MAMMOGRAPHY SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
TABLE 6 IMPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
TABLE 7 EXPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
TABLE 8 PRICES OF CANCER DIAGNOSTIC PRODUCTS
TABLE 9 CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 10 CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 11 CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2019–2026 (USD MILLION)
TABLE 12 CANCER DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 13 CANCER DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 14 CANCER DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2019–2026 (USD MILLION)
TABLE 15 CANCER DIAGNOSTICS MARKET FOR OTHER CONSUMABLES, BY REGION, 2019–2026 (USD MILLION)
TABLE 16 CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 17 CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 18 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 19 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 20 CANCER DIAGNOSTICS MARKET FOR SLIDE STAINING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
TABLE 21 CANCER DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
TABLE 22 CANCER DIAGNOSTICS MARKET FOR CELL PROCESSORS, BY REGION, 2019–2026 (USD MILLION)
TABLE 23 CANCER DIAGNOSTICS MARKET FOR PCR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 24 CANCER DIAGNOSTICS MARKET FOR NGS INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 25 CANCER DIAGNOSTICS MARKET FOR MICROARRAYS, BY REGION, 2019–2026 (USD MILLION)
TABLE 26 CANCER DIAGNOSTICS MARKET FOR OTHER PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 27 CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 28 CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 29 CANCER DIAGNOSTICS MARKET FOR CT SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
TABLE 30 CANCER DIAGNOSTICS MARKET FOR ULTRASOUND SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
TABLE 31 CANCER DIAGNOSTICS MARKET FOR MRI SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
TABLE 32 CANCER DIAGNOSTICS MARKET FOR MAMMOGRAPHY SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
TABLE 33 CANCER DIAGNOSTICS MARKET FOR NUCLEAR IMAGING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
TABLE 34 CANCER DIAGNOSTICS MARKET FOR BIOPSY INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 35 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 36 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 37 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY REGION, 2019–2026 (USD MILLION)
TABLE 38 CANCER DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2019–2026 (USD MILLION)
TABLE 39 CANCER DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019–2026 (USD MILLION)
TABLE 40 CANCER DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2019–2020 (USD MILLION)
TABLE 41 CANCER DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
TABLE 42 CANCER DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY REGION, 2019–2026 (USD MILLION)
TABLE 43 CANCER DIAGNOSTICS MARKET FOR MICROARRAY, BY REGION, 2019–2026 (USD MILLION)
TABLE 44 CANCER DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY REGION, 2019–2026 (USD MILLION)
TABLE 45 CANCER DIAGNOSTICS MARKET FOR OTHER IVD TECHNOLOGIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 46 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 47 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 48 CANCER DIAGNOSTICS MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2019–2026 (USD MILLION)
TABLE 49 CANCER DIAGNOSTICS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2019–2026 (USD MILLION)
TABLE 50 CANCER DIAGNOSTICS MARKET FOR NUCLEAR IMAGING, BY REGION, 2019–2026 (USD MILLION)
TABLE 51 CANCER DIAGNOSTICS MARKET FOR MAMMOGRAPHY, BY REGION, 2019–2026 (USD MILLION)
TABLE 52 CANCER DIAGNOSTICS MARKET FOR ULTRASOUND, BY REGION, 2019–2026 (USD MILLION)
TABLE 53 CANCER DIAGNOSTICS MARKET FOR BIOPSIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 54 CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 55 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 56 CANCER DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
TABLE 57 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 58 CANCER DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
TABLE 59 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 60 CANCER DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2026 (USD MILLION)
TABLE 61 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 62 CANCER DIAGNOSTICS MARKET FOR MELANOMA, BY REGION, 2019–2026 (USD MILLION)
TABLE 63 CANCER DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 64 CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 65 CANCER DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION)
TABLE 66 CANCER DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 67 CANCER DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 68 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 70 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 71 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 73 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 74 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 75 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 76 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 77 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 78 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 79 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 80 US: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 81 US: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 82 US: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 83 US: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 US: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 85 US: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 86 US: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 US: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 US: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 89 US: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 90 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 91 CANADA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 92 CANADA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 93 CANADA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 CANADA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 95 CANADA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 CANADA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 97 CANADA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 98 CANADA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 CANADA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 100 CANADA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 101 EUROPE: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 102 EUROPE: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 103 EUROPE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 EUROPE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 EUROPE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 106 EUROPE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 107 EUROPE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 108 EUROPE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 EUROPE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 110 EUROPE: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 111 EUROPE: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 112 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 113 GERMANY: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 114 GERMANY: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 115 GERMANY: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 GERMANY: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 GERMANY: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 118 GERMANY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 119 GERMANY: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 120 GERMANY: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 GERMANY: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 122 GERMANY: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 123 UK: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 124 UK: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 125 UK: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 126 UK: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 127 UK: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 128 UK: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 129 UK: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 130 UK: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 131 UK: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 132 UK: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 133 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 134 FRANCE: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 135 FRANCE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 136 FRANCE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 137 FRANCE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 138 FRANCE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 139 FRANCE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 140 FRANCE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 141 FRANCE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 142 FRANCE: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 143 FRANCE: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 144 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 145 ITALY: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 146 ITALY: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 147 ITALY: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 148 ITALY: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 149 ITALY: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 150 ITALY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 151 ITALY: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 152 ITALY: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 153 ITALY: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 154 ITALY: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 155 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 156 SPAIN: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 157 SPAIN: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 158 SPAIN: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 159 SPAIN: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 160 SPAIN: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 161 SPAIN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 162 SPAIN: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 163 SPAIN: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 164 SPAIN: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 165 SPAIN: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 166 LUNG CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025
TABLE 167 LIVER CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025
TABLE 168 BREAST CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025
TABLE 169 ROE: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 170 ROE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 171 ROE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 172 ROE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 173 ROE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 174 ROE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 175 ROE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 ROE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 177 ROE: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 178 ROE: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 179 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 180 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 181 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 182 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 183 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 184 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 185 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 186 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 187 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 188 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 189 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 190 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 191 CHINA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 192 CHINA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 193 CHINA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 194 CHINA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 CHINA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 196 CHINA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 197 CHINA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 198 CHINA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 199 CHINA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 200 CHINA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 201 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 202 JAPAN: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 203 JAPAN: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 204 JAPAN: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 205 JAPAN: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 206 JAPAN: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 207 JAPAN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 208 JAPAN: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 209 JAPAN: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 210 JAPAN: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 211 JAPAN: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 212 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 213 INDIA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 214 INDIA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 215 INDIA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 216 INDIA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 217 INDIA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 218 INDIA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 219 INDIA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 220 INDIA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 221 INDIA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 222 INDIA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 223 INCIDENCE OF CANCER IN ROAPAC COUNTRIES
TABLE 224 ROAPAC: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 225 ROAPAC: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 226 ROAPAC: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 227 ROAPAC: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 228 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 229 ROAPAC: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 230 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 231 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 232 ROAPAC: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 233 ROAPAC: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 234 ROW: CANCER DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 235 ROW: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 236 ROW: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 237 ROW: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 238 ROW: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 239 ROW: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 240 ROW: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 241 ROW: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 242 ROW: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 243 ROW: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 244 ROW: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 245 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 246 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 247 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 248 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 249 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 250 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 251 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 252 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 253 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 254 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 255 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 256 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 257 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 258 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 259 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 260 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 261 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 262 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 263 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 264 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 265 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 266 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 267 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 268 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 269 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES: DEGREE OF COMPETITION
TABLE 270 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS: DEGREE OF COMPETITION
TABLE 271 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–APRIL 2021
TABLE 272 KEY DEALS, JANUARY 2018–APRIL 2021
TABLE 273 OTHER KEY DEVELOPMENTS, JANUARY 2018–APRIL 2021
TABLE 274 COMPANY FOOTPRINT
TABLE 275 COMPANY PRODUCT FOOTPRINT
TABLE 276 COMPANY APPLICATION FOOTPRINT
TABLE 277 COMPANY GEOGRAPHICAL FOOTPRINT
TABLE 278 GE HEALTHCARE: BUSINESS OVERVIEW
TABLE 279 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
TABLE 280 F. HOFFMAN-LA ROCHE LTD.: BUSINESS OVERVIEW
TABLE 281 DANAHER CORPORATION: BUSINESS OVERVIEW
TABLE 282 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
TABLE 283 ABBOTT LABORATORIES: BUSINESS OVERVIEW
TABLE 284 QIAGEN N.V.: BUSINESS OVERVIEW
TABLE 285 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
TABLE 286 ILLUMINA INC.: BUSINESS OVERVIEW
TABLE 287 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
TABLE 288 DIASORIN S.P.A.: BUSINESS OVERVIEW
TABLE 289 MYRIAD GENETICS INC.: BUSINESS OVERVIEW
TABLE 290 HOLOGIC, INC.: BUSINESS OVERVIEW
TABLE 291 BIOMΙRIEUX SA: BUSINESS OVERVIEW
TABLE 292 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
TABLE 293 QUIDEL CORPORATION: BUSINESS OVERVIEW
TABLE 294 EXACT SCIENCES: BUSINESS OVERVIEW
TABLE 295 BIOCARTIS NV: BUSINESS OVERVIEW
TABLE 296 CANCER DIAGNOSTICS INC.: BUSINESS OVERVIEW
TABLE 297 AMOY DIAGNOSTICS CO. LTD.: BUSINESS OVERVIEW
TABLE 298 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
TABLE 299 BIO SB: BUSINESS OVERVIEW
TABLE 300 VELA DIAGNOSTICS: BUSINESS OVERVIEW

LIST OF FIGURES (48 Figures)

FIGURE 1 RESEARCH DESIGN
FIGURE 2 PRIMARY SOURCES
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 6 TOP-DOWN APPROACH
FIGURE 7 DATA TRIANGULATION METHODOLOGY
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
FIGURE 10 CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021 VS. 2026 (USD BILLION)
FIGURE 11 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD BILLION)
FIGURE 12 CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)
FIGURE 13 CANCER DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 14 CANCER DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD BILLION)
FIGURE 15 INCREASING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
FIGURE 16 INSTRUMENTS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020
FIGURE 17 US DOMINATED THE NORTH AMERICAN CANCER DIAGNOSTICS MARKET IN 2020
FIGURE 18 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 19 CANCER DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 20 RISING NUMBER OF PERSONALIZED MEDICINES, 2008–2020
FIGURE 21 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASES
FIGURE 22 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
FIGURE 23 510(K) APPROVAL PROCESS
FIGURE 24 NORTH AMERICA: CANCER DIAGNOSTICS MARKET SNAPSHOT
FIGURE 25 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET SNAPSHOT
FIGURE 26 KEY DEVELOPMENTS IN THE CANCER DIAGNOSTICS MARKET, JANUARY 2018–APRIL 2021
FIGURE 27 MARKET EVOLUTION MATRIX: JANUARY 2018 TO APRIL 2021
FIGURE 28 VENDOR DIVE: CANCER DIAGNOSTICS MARKET
FIGURE 29 VENDOR DIVE MATRIX FOR SMES & START-UPS: CANCER DIAGNOSTICS MARKET
FIGURE 30 GE HEALTHCARE: COMPANY SNAPSHOT (2020)
FIGURE 31 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
FIGURE 33 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
FIGURE 37 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2020)
FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
FIGURE 40 DIASORIN S.P.A.: COMPANY SNAPSHOT (2019)
FIGURE 41 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2020)
FIGURE 42 HOLOGIC INC.: COMPANY SNAPSHOT (2020)
FIGURE 43 BIOMΙRIEUX SA: COMPANY SNAPSHOT (2020)
FIGURE 44 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
FIGURE 45 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
FIGURE 46 EXACT SCIENCES: COMPANY SNAPSHOT (2020)
FIGURE 47 BIOCARTIS NV: COMPANY SNAPSHOT (2020)
FIGURE 48 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)

      The study involved four major activities in estimating the current size of the cancer diagnostics market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (hospitals and diagnostic laboratories) and supply sides (cancer diagnostic manufacturers and distributors).

      The following is a breakdown of the primary respondents:

      Cancer Diagnostics Market   Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the cancer diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry and markets have been identified through extensive secondary research
      • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Data Triangulation

      After arriving at the overall market size-using the market size estimation processesthe market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the cancer diagnostics industry.

      Report Objectives

      • To define, describe, and forecast the global cancer diagnostics market based on product, technology, application, end user, and region
      • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
      • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
      • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
      • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
      • To track and analyze competitive developments such as acquisitions, new product launches, expansions, regulatory approvals, and agreements in the cancer diagnostics market

      Available Customizations:

      With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

        Product Analysis:

        • Product matrix, which gives a detailed comparison of the product portfolios of each company

        Geographic Analysis:

        • Further breakdown of the Rest of the World cancer diagnostics market into Latin America, the Middle East, and Africa cancer diagnostics market into specific countries and further breakdown of the European cancer diagnostics market into specific countries
      COVID-19

      Get in-depth analysis of the COVID-19 impact on the Cancer Diagnostics Market

      Benchmarking the rapid strategy shifts of the Top 100 companies in the Cancer Diagnostics Market

      Request For Special Pricing
      Report Code
      MD 3480
      Published ON
      Apr, 2021
      Choose License Type
      BUY NOW
      • SHARE
      X
      Request Customization
      Speak to Analyst
      Speak to Analyst
      OR FACE-TO-FACE MEETING
      PERSONALIZE THIS RESEARCH
      • Triangulate with your Own Data
      • Get Data as per your Format and Definition
      • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
      • Any level of Personalization
      REQUEST A FREE CUSTOMIZATION
      LET US HELP YOU!
      • What are the Known and Unknown Adjacencies Impacting the Cancer Diagnostics Market
      • What will your New Revenue Sources be?
      • Who will be your Top Customer; what will make them switch?
      • Defend your Market Share or Win Competitors
      • Get a Scorecard for Target Partners
      CUSTOMIZED WORKSHOP REQUEST
      ADJACENT MARKETS
      REQUEST BUNDLE REPORTS
      +1-888-600-6441
      • Call Us
      • +1-888-600-6441 (Corporate office hours)
      • +1-888-600-6441 (US/Can toll free)
      • +44-800-368-9399 (UK office hours)
      CONNECT WITH US
      ABOUT TRUST ONLINE
      ©2021 MarketsandMarkets Research Private Ltd. All rights reserved
      ...

      Digital Virtual Assistant - MarketsandMarkets

      Home